Multidisciplinary management of adolescents and young adults (AYA) sarcoma : A successful effort of an adult high-volume cancer center
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
INTRODUCTION: The aim of this retrospective study was to investigate the clinicopathological characteristics of AYA sarcomas and their clinical outcomes at a high-volume single center.
METHODS: Demographic, clinicopathological data on the diagnosis, treatment and follow-up of all sarcoma patients aged 16-39 years (ys) observed at our Institute between January 2010 and December 2021 were retrospectively collected, including diagnostic (TTD) and treatment delay(TTT), clinical outcomes (OS and PFS), and late-treatment effects.
RESULTS: We identified 228 AYA patients, median age 30 years, 29% ≤ 25 years, 57% males, 88% soft tissue sarcomas (STS), and 12% bone sarcomas (BS). Among STSs, 13% were small round cell tumors (SRCT), 52% intermediate-high-grade, 24% low-grade STSs. Among BS, 32% were high-grade. Median TTD and TTT were 120 (0-8255) and 7 days (0-83), respectively. Surgery was performed in 83%, radiotherapy in 29%, and systemic therapy in 27%. Median follow-up was 72.9 months(1.6-145), 5-year and 10-year OS were 78.5% and 62%, respectively. Kaplan-Meyer analysis showed a significantly better 5-year OS and PFS for patients with >92 days of TTD (OS 85.7% vs. 66.7%, p = 0.001, PFS 50.2% vs. 24.9%, p = 0.009). According to age (≤25 years vs. > 25 years), 5-year OS was 69.8% versus 82.2%, respectively (p = 0.047).
CONCLUSION: Our analysis confirmed previous data on sarcoma AYA patients followed in a referral center. Unexpectedly, diagnostic delay was not associated with poor OS and PFS. Patients <25 years showed a poorer prognosis due to the higher incidence of SRCT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cancer medicine - 12(2023), 15 vom: 12. Aug., Seite 16254-16263 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bertuzzi, Alexia Francesca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
AYA |
|---|
| Anmerkungen: |
Date Completed 01.09.2023 Date Revised 02.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cam4.6289 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358676185 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358676185 | ||
| 003 | DE-627 | ||
| 005 | 20231226075242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.6289 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358676185 | ||
| 035 | |a (NLM)37366268 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bertuzzi, Alexia Francesca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multidisciplinary management of adolescents and young adults (AYA) sarcoma |b A successful effort of an adult high-volume cancer center |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.09.2023 | ||
| 500 | |a Date Revised 02.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
| 520 | |a INTRODUCTION: The aim of this retrospective study was to investigate the clinicopathological characteristics of AYA sarcomas and their clinical outcomes at a high-volume single center | ||
| 520 | |a METHODS: Demographic, clinicopathological data on the diagnosis, treatment and follow-up of all sarcoma patients aged 16-39 years (ys) observed at our Institute between January 2010 and December 2021 were retrospectively collected, including diagnostic (TTD) and treatment delay(TTT), clinical outcomes (OS and PFS), and late-treatment effects | ||
| 520 | |a RESULTS: We identified 228 AYA patients, median age 30 years, 29% ≤ 25 years, 57% males, 88% soft tissue sarcomas (STS), and 12% bone sarcomas (BS). Among STSs, 13% were small round cell tumors (SRCT), 52% intermediate-high-grade, 24% low-grade STSs. Among BS, 32% were high-grade. Median TTD and TTT were 120 (0-8255) and 7 days (0-83), respectively. Surgery was performed in 83%, radiotherapy in 29%, and systemic therapy in 27%. Median follow-up was 72.9 months(1.6-145), 5-year and 10-year OS were 78.5% and 62%, respectively. Kaplan-Meyer analysis showed a significantly better 5-year OS and PFS for patients with >92 days of TTD (OS 85.7% vs. 66.7%, p = 0.001, PFS 50.2% vs. 24.9%, p = 0.009). According to age (≤25 years vs. > 25 years), 5-year OS was 69.8% versus 82.2%, respectively (p = 0.047) | ||
| 520 | |a CONCLUSION: Our analysis confirmed previous data on sarcoma AYA patients followed in a referral center. Unexpectedly, diagnostic delay was not associated with poor OS and PFS. Patients <25 years showed a poorer prognosis due to the higher incidence of SRCT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a AYA | |
| 650 | 4 | |a adolescent | |
| 650 | 4 | |a oncology | |
| 650 | 4 | |a sarcoma | |
| 650 | 4 | |a young adult | |
| 700 | 1 | |a Grimaudo, Maria Susanna |e verfasserin |4 aut | |
| 700 | 1 | |a Laffi, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Giordano, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Gennaro, Nicolò |e verfasserin |4 aut | |
| 700 | 1 | |a Cariboni, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Siracusano, Licia Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Quagliuolo, Vittorio |e verfasserin |4 aut | |
| 700 | 1 | |a Colombo, Piergiuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Federico, D'Orazio |e verfasserin |4 aut | |
| 700 | 1 | |a Renne, Salvatore Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Specchia, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Cananzi, Ferdinando |e verfasserin |4 aut | |
| 700 | 1 | |a Marrari, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Navarria, Pierina |e verfasserin |4 aut | |
| 700 | 1 | |a Daolio, Primo Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Bastoni, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Armando |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g 12(2023), 15 vom: 12. Aug., Seite 16254-16263 |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:15 |g day:12 |g month:08 |g pages:16254-16263 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.6289 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 15 |b 12 |c 08 |h 16254-16263 | ||